ACADIA Pharmaceuticals (MEX:ACAD) Cyclically Adjusted Revenue per Share: MXN73.30 (As of Mar. 2026)


MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
73 GF Score
Price MXN460.50
GF Value MXN442.40
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Cyclically Adjusted Revenue per Share?

ACADIA Pharmaceuticals MEX:ACAD +27.21% 73 Cyclically Adjusted Revenue per Share is MXN73.30 as of Mar. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN442.40 (Fairly Valued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted revenue per share for the three months ended in Mar. 2026 was MXN27.989. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN73.30 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ACADIA Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was 13.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 18.30% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 25.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ACADIA Pharmaceuticals was 51.30% per year. The lowest was 18.30% per year. And the median was 33.90% per year.

As of today (2026-07-08), ACADIA Pharmaceuticals's current stock price is MXN460.50. ACADIA Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN73.30. ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 6.28.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ACADIA Pharmaceuticals was 151.08. The lowest was 4.53. And the median was 16.83.


ACADIA Pharmaceuticals  (MEX:ACAD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=460.50/73.30
=6.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ACADIA Pharmaceuticals was 151.08. The lowest was 4.53. And the median was 16.83.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ACADIA Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms


ACADIA Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.96 62.08 43.73 86.27 58.75

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 98.67 78.58 70.93 58.75 73.30

MEX:ACAD vs VKTX, EWTX, DNLI: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


MEX:ACAD
73GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ACADIA Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=27.989/330.2130*330.2130
=27.989

Current CPI (Mar. 2026) = 330.2130.

ACADIA Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.016 241.018 0.022
201609 0.867 241.428 1.186
201612 2.034 241.432 2.782
201703 2.366 243.801 3.205
201706 4.511 244.955 6.081
201709 5.271 246.819 7.052
201712 6.892 246.524 9.232
201803 7.118 249.554 9.419
201806 8.977 251.989 11.764
201809 8.724 252.439 11.412
201812 8.883 251.233 11.676
201903 8.482 254.202 11.018
201906 11.075 256.143 14.278
201909 12.798 256.759 16.459
201912 11.997 256.974 15.416
202003 13.593 258.115 17.390
202006 16.235 257.797 20.795
202009 16.845 260.280 21.371
202012 15.113 260.474 19.159
202103 13.612 264.877 16.970
202106 14.297 271.696 17.376
202109 16.844 274.310 20.277
202112 16.454 278.802 19.488
202203 14.260 287.504 16.378
202206 16.746 296.311 18.662
202209 16.245 296.808 18.073
202212 16.427 296.797 18.276
202303 13.159 301.836 14.396
202306 17.164 305.109 18.576
202309 22.453 307.789 24.089
202312 23.795 306.746 25.615
202403 20.502 312.332 21.676
202406 26.676 314.175 28.038
202409 29.670 315.301 31.073
202412 32.412 315.605 33.912
202503 29.811 319.799 30.782
202506 29.532 322.561 30.233
202509 29.952 324.800 30.451
202512 29.693 324.054 30.257
202603 27.989 330.213 27.989

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN73.30 mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Cyclically Adjusted Revenue per Share of MXN73.30 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Cyclically Adjusted Revenue per Share too high?
ACADIA Pharmaceuticals' current Cyclically Adjusted Revenue per Share is MXN73.30. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Cyclically Adjusted Revenue per Share compare to VKTX and EWTX?
ACADIA Pharmaceuticals' Cyclically Adjusted Revenue per Share of MXN73.30 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Cyclically Adjusted Revenue per Share is MXN73.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN442.40, compared to a current price of MXN460.50 — trading 4.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN73.30. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Cyclically Adjusted Revenue per Share is MXN73.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN460.50 is trading 4.1% above its estimated GF Value™ of MXN442.40. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Cyclically Adjusted Revenue per Share: MXN73.30
  • GF Value™: MXN442.40 vs. price of MXN460.50 (4.1% above fair value)
  • GF Score™: 73/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score

Get the complete analysis for MEX:ACAD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN460.50
Price
MXN442.40
GF Value